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b Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, United StatesPatients with B-precursor acute lymphoblastic leukemia (BPL) are
often treated with TBI-based conditioning, followed by hematopoietic
stem-cell transplantation (HSCT). However, the leukemic relapse in
high-risk BPL patients remained the major cause of patient mortality
(Gaynon et al., 2006; Balduzzi et al., 2014). The incidence of post-
HSTC relapse correlated with the level of residual leukemia burden
prior to total body irradiation (TBI), indicating the radiation-resistant
population of BPL cells may have contributed to the relapse. STAT-3 sig-
naling pathway, alongwith PI3-K andNFkB pathways, regulates the cell
survival after exposure to radiation-induced oxidative stress (Uckun
et al., 2010), therefore contributes to the radiation resistance of BPL
cells. Spleen tyrosine kinase (SYK), a key regulator of STAT-3, was
chosen as the main target of reducing the radiation resistance (Mocsai
et al., 2010). The authors identiﬁed C61, a small-molecule chemical
compound inhibitor for SYK phosphorylation, which sensitized the
resistant BPL cells toward radiation.
Despite the high selectivity and potent inhibition of C61 against SYK
phosphorylation, the in vivo performance of C61 is still limited by phar-
macokinetic problems. The low molecular weight of C61 is expected to
have short blood circulation and quickly be cleared through the kidney
(Levchenko et al., 2002). The in vivo stability of C61 against various pro-
teases needs to be addressed. In the current issue of EBioMedicine,
Uckun et al. used liposome nanoparticles to encapsulate C61, increased
its blood retention and preserved its integrity for proper function
(Uckun et al., 2015). The liposome formulation could also alleviate the
potential toxic side effects of free C61 (Elbayoumi and Torchilin, 2010).
In their recent work published in EBioMedicine, Uckun et al. ﬁrst
studied the correlation between SYK-STAT3 pathway and incidence of
relapse in primary ALL samples. The results conﬁrmed that SYK was a
key regulator for STAT3 regulation, while patients with early relapse
had signiﬁcantly higher expression levels of SYK-STAT3 genes. The au-
thors then conﬁrmed with in vitro that C61-liposome in combination
with low-dose TBI, could deplete leukemia-initiating BPL cells. The
xenograft model study showed promising results that the C61-
liposome + TBI regimen resulted in a median EFS time of N150 days
and a remarkable 150-day leukemia-free survival of 80 ± 10%. TheDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.005.
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2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).authors then evaluated the treatment efﬁcacy in CD22ΔE12xBCR-ABL
double transgenic (Tg) model of advanced murine BPL. The combina-
tion regiment had the longest duration of remission (54 ± 27 days)
compared to TBI (7 ± 4 days, p = 0.021) or C61-liposome (0 ±
0 days, p = 0.0016). The median OS times were 112 days for C61-
LNP + TBI but only 4 days for CON (Log-rank test, P b 0.0001), 3 days
for C61-LNP alone (P b 0.0001), and 14 days for TBI alone (P= 0.0002).
In general, the authors presented an interesting nanoparticle formu-
lation for the radiosensitization of BPL. The animal studies proved that
C61-liposome + TBI is a promising treatment strategy to overcome
BPL relapse.
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